We use cookies for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Make the most of 2022 Lead your own way in business and beyond with our unrivalled journalism.
Add this topic to your myFT Digest for news straight to your inbox
Surge in young patients in England, France and US but the vast majority have mild symptoms
Chief executive deSouza attacks regulatory intervention over cancer test company
Pharma executive warns policymakers may be incapable of preparing the public for next pandemic
Admissions hit record high but some patients are seeking care for reasons unrelated to virus
Healthcare experts say Biden administration failed to prepare for soaring demand from latest wave
Stand-off comes as Biden administration tries to keep children in class despite Omicron virus surge
With more than 270 people dying every day, authorities are under pressure to treat, rather than prosecute, users
Pharma executives say threats of tougher scrutiny put future of sector at risk
No need for variant-specific jabs yet, according to Joe Biden’s chief medical adviser
Covid death toll reaches 800,000 as threat from new variant looms over stretched hospitals
Emergence of mutation prompts virologists to weigh competing theories
Preliminary research suggests two shots show significantly reduced effectiveness against new coronavirus variant
Executive says patients on other medications will not be able to take competing antiviral treatment
Experts advising FDA recommend treatment for high-risk patients amid fears over Omicron variant
WHO says differing predictions from Oxford, BioNTech and Moderna are ‘premature’
Stéphane Bancel foresees ‘material drop’ in current jabs’ effectiveness, sending stocks and oil prices lower
Health officials warn of surge in infections as millions of Americans travel for the holiday
Ohio ruling is first time CVS, Walgreens and Walmart have been held culpable at conclusion of a trial
Regulators pave the way for supplemental doses amid worries about waning immunity and rising cases
Plan to spin off consumer division has failed to thrill investors
Vote by European Medicines Agency panel deals setback to controversial $56,000-a-year treatment
Company applies for regulatory greenlight after reaching deal to expand access to medication in developing countries
BD chief says pandemic is coming ‘under control’ but prices will not return to previous levels
New medicines from Pfizer and Merck could take some pressure off hospitals. But will they work on the already vaccinated?
World’s largest healthcare group follows trend to slim down with plans to focus on pharmaceuticals
International Edition
